Ono, BMS submit supplemental application in Japan for Orencia to treat JIA

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) and Bristol-Myers Squibb Co. (NYSE:BMY) submitted a supplemental application in Japan for IV Orencia abatacept (ONO-4164IV) to treat active polyarticular juvenile idiopathic arthritis (JIA). The CTLA-4 (CD152)-Ig fusion protein is approved in Japan to treat rheumatoid arthritis (RA)...